| Bid | 2.18 |
| Market Cap | 108.02M |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -2.16 |
| PE Ratio (ttm) | -1.02 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 2.22 |
| Volume | 1,349,544 |
| Avg. Volume (20D) | 2,494,337 |
| Open | 2.20 |
| Previous Close | 2.16 |
| Day's Range | 2.11 - 2.25 |
| 52-Week Range | 1.76 - 26.35 |
| Beta | undefined |
About CABA
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor (CAAR) T cells that are designed to selectively bind and eliminate B cells, which produce disease-causing autoantibodies or pathogenic B cells. The company's lead product candidate is DSG3-CAART,...
Analyst Forecast
According to 8 analyst ratings, the average rating for CABA stock is "Buy." The 12-month stock price forecast is $27.5, which is an increase of 1144.34% from the latest price.
2 months ago · seekingalpha.com
Cabaletta: Biotech With Large Potential, Interesting Bottom Pattern, Plenty Of CashI am buying Cabaletta Bio shares as a speculative play on upcoming clinical trial updates for innovative CAR-T therapies. Despite high volatility in 2024 and the potential for total investment loss, t...